Loading data for ACTU — first visit, this takes a few seconds.

Actuate Therapeutics, Inc. Common stock (ACTU)

NasdaqGM: ACTU · 实时价格 · USD

1.44

+0.07 (5.11%)

收盘价： Sep 04, 2026, 3:59 PM

1.38

-6.76%

盘后: 7:56 PM

提醒

Alert

股价、关键数字和最新消息，都在这一页。

5.10% (1D)

买价	0.8
市值	35.5M
营收（TTM）	n/a
净利润（TTM）	-20.5M
	0.96
	-0.87
	n/a
	-2.23
市净率（TTM）	36.10
市销率（TTM）	0.00
财报日期	Nov 12, 2026

卖价	1.45
成交量	1,095,799
20日均量	358,926
开盘价	1.45
前收盘价	1.37
日内区间	1.33 - 1.73
52周区间	0.90 - 8.80
分析师	n/a
目标价	n/a
分红	n/a
除息日	n/a

关于 ACTU

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma. It also develops elraglusib, which is in Phase 1/2 trial for the treatment of refractory pediatric malignancies, including Ewing...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Aug 13, 2024

员工人数 12

交易所 NasdaqGM

股票代码 ACTU

官网 https://actuatetherapeutics.com

公司完整简介

财务表现

2025年，Actuate Therapeutics Common stock的营收为0，较上一年的0增长undefined%。净利润为-22.23M，下降-18.54%。

财务报表

财报意外

Actuate Therapeutics Common stock 已于 Aug 14, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.2 低于预期 0.00, ， 33.33% 同比增长.

下次财报发布时间

Actuate Therapeutics, Inc. Common stock 的下次财报预计于 Nov 12, 2026, 盘中。
分析师预计营收为 ... 升级

股价变动原因

新闻

3天前 · Zacks

All You Need to Know About Actuate Therapeutics, Inc. (ACTU) Rating Upgrade to Buy

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

7月前 · Simply Wall St.

Actuate Therapeutics, Inc.'s (NASDAQ:ACTU) market cap dropped US$13m last week; Private equity firms bore the brunt

Key Insights The considerable ownership by private equity firms in Actuate Therapeutics indicates that they...

8月前 · MT Newswires

Actuate Therapeutics Plans to Advance Elraglusib in Ewing Sarcoma After Phase 1 Data

Actuate Therapeutics (ACTU) said Tuesday it plans to advance elraglusib in Ewing sarcoma and potenti

8月前 · Zacks

Actuate Therapeutics, Inc. (ACTU) Upgraded to Buy: What Does It Mean for the Stock?

Actuate Therapeutics, Inc. (ACTU) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

9月前 · Zacks

How Much Upside is Left in Actuate Therapeutics, Inc. (ACTU)? Wall Street Analysts Think 214.06%

The average of price targets set by Wall Street analysts indicates a potential upside of 214.1% in Actuate Therapeutics, Inc. (ACTU). While the effectiveness of this highly sought-after metric is ques...

第 1 页，共 2 页

Actuate Therapeutics, Inc. Common stock (ACTU)